Company
Artiva
Artiva Biotherapeutics: Unlocking NK Cell Therapy for Autoimmune Diseases
Also known as Artiva Biotherapeutics, Artiva Biotherapeutics, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- San Diego, California, United States
- Customers
- patients with autoimmune diseases
- Legal name
- Artiva Biotherapeutics, Inc.
- artivabio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies.
Funding snapshot
- Total raised
- $163MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $120M2021-02-22
Funding rounds
- Round, 2021
- $120M2021-02-22, SEC form D sold, 27 investors
- Round, 2020
- $43.4M2020-06-25, SEC form D sold, 8 investors
Products
- Other
- AlloNK
- Web
- AlloNK®
Loading relationship preview